To provide a comprehensive overview of antibody-based therapeutic strategies for AML, focusing on bispecific T cell engagers (BTCEs) in preclinical development or early clinical trials, particularly in the context of treatment challenges.
Key Findings:
Only gemtuzumab ozogamicin (GO) has received FDA approval for AML.
BTCEs can bind to two distinct antigens, activating T cells to target and destroy malignant cells.
Strategies such as PEGylation and multimerization are being explored to enhance the pharmacokinetics of BTCEs.
Interpretation:
Limitations:
The challenge of identifying AML-specific surface antigens complicates the development of effective therapies.
Most candidate targets for CAR-T cell therapies are also present on normal cells, raising safety concerns.
Conclusion:
The review discusses the challenges that remain in the development of antibody-based therapies, particularly BTCEs, without making unsupported claims about their potential.
